Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Recs

0

Why Ionis Pharmaceuticals Rallied 12% in February

 

What happened

After reporting better-than-expected results in the fourth quarter and providing investors with an update on its R&D progress, shares in Ionis Pharmaceuticals (NASDAQ: IONS  ) increased more than 12% last month, according to S&P Global Market Intelligence

So what

Ionis Pharmaceuticals has a lot of drugs in clinical trials, and many of those drugs are partnered up with bigger peers that pay the company licensing and milestone revenue. 

A businessman announces news with a megaphone in front of a chart showing a rising stock price.

IMAGE SOURCE: GETTY IMAGES.

In Q4, payments from its peers propelled the company's top line up 213% year over year to $159.3 million. The windfall allowed the company to report quarterly net income of $25.9 million, up 136% from the same period in 2015. Both figures were better than what industry watchers were predicting. Overall, revenue was $347 million in 2016, up 45% from 2015. 

The company also updated investors on its clinical trials, offering an outlook that suggests this year will be rich in study data. The company hopes to file volanesorsen for FDA approval for use in familial chylomicronemia syndrome following its reporting of positive phase 3 results earlier this month.

It also hopes to see regulatory applications get filed for IONIS-TTrx, a drug in trials evaluating its use in familial amyloid polyneuropathy. Results from phase 3 studies are expected in the first half of this year, and if they're good, that could allow collaboration partners GlaxoSmithKline to pitch it to regulators.

Management hopes to add as many as five new drug candidates to its clinical-stage drug pipeline this year. 

Now what

In December, the FDA gave a green light to Spinraza, a drug licensed to Biogen that targets spinal muscular atrophy, a rare disease. Sales should grow throughout this year, and given a lack of treatment alternatives, and a six-figure price tag, royalties in the teen percentages could be meaningful to Ionis Pharmaceuticals relatively quickly.  

The company's volanesorsen phase 3 data was good enough for management to say it will advance it to the FDA. Investors should find out if IONIS-TTrx phase 3 trials were a success in Q2. 

Overall, Ionis Pharmaceuticals' target is to become profitable on a pro-forma basis in 2017, and if it does, it will mark an important milestone for this mid-cap biotech stock, and for that reason, investors are right to be optimistic.

10 stocks we like better than Ionis Pharmaceuticals
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now...and Ionis Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of February 6, 2017.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 4006645, ~/Articles/ArticleHandler.aspx, 3/23/2017 12:20:42 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
Change up DOW 20738.2 76.9 0.4%
Change up S&P 500 2356.8 8.4 0.4%
Change up NASD 5839.3 17.6 0.3%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

3/23/2017 12:04 PM
IONS $38.99 Up +0.85 +2.23%
Ionis Pharmaceutic… CAPS Rating: *****
BIIB $279.00 Up +1.13 +0.41%
Biogen CAPS Rating: *****
GSK $42.54 Up +0.26 +0.61%
GlaxoSmithKline CAPS Rating: ***

Article registration testing
VISIBLE INTERNALLY ONLY AND ONLY WORKS WITH UNREGISTERED VISITORS

Revisit this page

Clear article's cache and revisit this page

Or, visit the current page, forcing Test ID to article:interrupt:106919 and

Tookie Value = 00672289342501152048090524815876

Advertisement